Vaccine efficacy of CoronaVac against COVID-19 in children in Brazil during the Omicron period

  • Frenck, RW et al. Safety, immunogenicity and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N.Engl. J.Med. 385239-250 (2021).

    CAS Google Scholar Article

  • Walter, EB et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years old. N.Engl. J.Med. 38635–46 (2022).

    CAS Google Scholar Article

  • Center for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). (2020). Available at: https://emergency.cdc.gov/han/2020/han00432.asp. (Accessed: May 14, 2020).

  • Stein, M. et al. Project report The burden of COVID-19 in children and its prevention through vaccination: a joint statement by the Israeli Pediatric Association and the Israeli Society for Pediatric Infectious Diseases. Vaccines ten81 (2022).

  • Ministry of Saude do Brasil. Technical Note Noh6/2022-Secovid/Gab/Secovid/Ms.. (2022).

  • Jara, A. et al. Efficacy of an inactivated vaccine against SARS-CoV-2 in children and adolescents: a large-scale observational study. SSRN (2022).

  • Jara, A. et al. Efficacy of CoronaVac in children 3-5 years old during the omicron SARS-CoV-2 outbreak. Nat. Med. 281377-1380 (2022).

  • Florentino, PTV et al. Vaccine efficacy of two-dose BNT162b2 over time against symptomatic COVID-19 infection and severe cases in adolescents: negatively designed case-control studies in Brazil and Scotland. The Lancet Infectious Diseases. 1–23 (2022).

  • Andrews, N et al. Efficacy of the Covid-19 vaccine against the Omicron variant (B.1.1.529). N.Engl. J.Med. 3861532-1546 (2022).

    CAS Google Scholar Article

  • Buchan, SA, Nguyen, L., Wilson, SE, Kitchen, SA, and Kwong, J. Vaccine efficacy of BNT162b2 versus Omicron and Delta findings in adolescents. medRxiv 2022.04.07.22273319 (2022).

  • Veneti, L. et al. Vaccine efficacy with BNT162b2 vaccine (Comirnaty, Pfizer-BioNTtech) against reported SARS-CoV-2 delta and omicron infection in adolescents, Norway, August 2021 to January 2022. SSRN electron. J 21–11 (2022).

    Google Scholar

  • Dorabawila, V. et al. Efficacy of the BNT162b2 vaccine in children 5-11 and 12-17 years old in New York after the emergence of the Omicron variant. medRxiv 2022.02.25.22271454 (2022).

  • Sacco, C. et al. Articles Efficacy of the BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis from January to April 2022. Lancet 21–7 (2022).

    Google Scholar

  • Vandenbroucke, J. & Pearce, N. Negative test design differences and commonalities with other case-control studies with “other patient” controls. Epidemiology 30838–844 (2019).

    Google Scholar article

  • Dawood, FS, Porucznik, CA, Veguilla, V. & Al, E. Incidence rate, household infection risk, and clinical features of SARS-CoV-2 infection in children and adults in the Utah and New York City, New York. Jama Pediatrics 17659–67 (2022).

    Google Scholar article

  • Mensah, AA et al. Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January 2020 and July 2021, in England. Lancet Child Teenager. Health 6384–392 (2022).

    CAS Google Scholar Article

  • Lipsitch, M., Goldstein, E., Ray, GT & Fireman, B. Susceptible subject exhaustion bias in studies of influenza vaccine decline: how to ensure robust results. Epidemiol. Infect. 147e306 (2019).

    CAS Google Scholar Article

  • Katikireddi, SV et al. Protection of the two-dose ChAdOx1 nCoV-19 vaccine against COVID-19-related hospitalizations and deaths over time: a population-based retrospective cohort study in Scotland and Brazil. Lancet 39925–35 (2022).

    CAS Google Scholar Article

  • Cerqueira-Silva, T. et al. Vaccine efficacy of heterologous CoronaVac plus BNT162b2 in Brazil. Nat. Medium. 28838–843 (2022).

  • Cerqueira-Silva, T. et al. Vaccination plus previous infection: protection during the omicron wave in Brazil. Lancet infect. Say. 221–2 (2022).

  • Cerqueira-Silva, T. et al. Efficacy of CoronaVac, ChAdOx1 nCoV-19, BNT162b2 and Ad26.COV2.S in people with previous SARS-CoV-2 infection in Brazil: a test-negative case-control study. Lancet infect. Say. 22791–801 (2022).

    CAS Google Scholar Article

  • Vandenbroucke, JP, Brickley, EB, Vandenbroucke-Grauls, CMJE & Pearce, N. A test-negative design with additional population controls can be used to rapidly investigate the causes of the SARS-COV-2 outbreak. Epidemiology 31836–843 (2020).

    Google Scholar article

  • Fiocruz. GISAID. Rede Genomica (2020). Available at: http://www.genomahcov.fiocruz.br/#. (Accessed: May 15, 2022)

  • Allik, M. et al. Small Area Deprivation Measure for Brazil: Data Documentation. University of Glasgow (2020). Available at: https://researchdata.gla.ac.uk/980/. (Accessed: May 15, 2020).

  • Vienna, AR Core Team. A: A language and environment for statistical computing. R foundation for statistical computing; (2021).

  • Wickham, H. et al. Welcome to the Tidyverse Tidyverse Package. J. Open Source Software. 41–6 (2019).

    Google Scholar article

  • van Buuren, S. & Groothuis-Oudshoorn, K. mouse: multivariate imputation by chained equations in R. J. Stat. Software 451–67 (2011).

    Google Scholar article

  • Firth, D. “Reducing the Bias of Maximum Likelihood Estimates.”. Biometrics 82667 (1995).

    MathSciNetGoogle Scholar

  • Benchimol, EI et al. The study report produced using the RECORD (Observational Routinely-collected health data) declaration. PLoS Med. 121–22 (2015).

    Google Scholar article

  • Sara H. Byrd